59.36
1.02 (1.75%)
| 前收盘价格 | 58.34 |
| 收盘价格 | 58.20 |
| 成交量 | 2,120,897 |
| 平均成交量 (3个月) | 2,914,204 |
| 市值 | 11,237,982,208 |
| 预期市盈率 (P/E Forward) | 90.91 |
| 价格/销量 (P/S) | 3.88 |
| 股市价格/股市净资产 (P/B) | 4.69 |
| 52周波幅 | |
| 利润日期 | 10 Nov 2025 |
| 营业毛利率 | -36.06% |
| 营业利益率 (TTM) | -11.53% |
| 稀释每股收益 (EPS TTM) | -5.53 |
| 季度收入增长率 (YOY) | 10.90% |
| 总债务/股东权益 (D/E MRQ) | 105.93% |
| 流动比率 (MRQ) | 2.73 |
| 营业现金流 (OCF TTM) | 323.66 M |
| 杠杆自由现金流 (LFCF TTM) | 163.08 M |
| 资产报酬率 (ROA TTM) | -1.83% |
| 股东权益报酬率 (ROE TTM) | -36.89% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Diagnostics & Research (US) | 看涨 | 混合的 |
| Diagnostics & Research (全球的) | 看涨 | 混合的 | |
| 股票 | Exact Sciences Corporation | 看涨 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 1.5 |
| 内部交易活动 | -1.5 |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.90 |
|
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening. |
|
| 部门 | Healthcare |
| 行业 | Diagnostics & Research |
| 投资方式 | Small Growth |
| 内部持股比例 | 0.92% |
| 机构持股比例 | 98.89% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 85.00 (Craig-Hallum, 43.19%) | 购买 |
| 中 | 65.00 (9.50%) | |
| 低 | 46.00 (RBC Capital, -22.51%) | 保留 |
| 平均值 | 63.86 (7.58%) | |
| 总计 | 5 购买, 2 保留 | |
| 平均价格@调整类型 | 51.05 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Piper Sandler | 08 Oct 2025 | 70.00 (17.92%) | 购买 | 59.32 |
| 11 Aug 2025 | 60.00 (1.08%) | 购买 | 40.91 | |
| Evercore ISI Group | 07 Oct 2025 | 68.00 (14.56%) | 购买 | 57.75 |
| 08 Aug 2025 | 64.00 (7.82%) | 购买 | 40.99 | |
| Barclays | 02 Oct 2025 | 65.00 (9.50%) | 购买 | 56.19 |
| 07 Aug 2025 | 55.00 (-7.35%) | 购买 | 43.16 | |
| Craig-Hallum | 11 Sep 2025 | 85.00 (43.19%) | 购买 | 56.00 |
| BTIG | 12 Aug 2025 | 60.00 (1.08%) | 购买 | 41.74 |
| RBC Capital | 07 Aug 2025 | 46.00 (-22.51%) | 保留 | 43.16 |
| UBS | 07 Aug 2025 | 53.00 (-10.71%) | 保留 | 43.16 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| DOYLE JAMES EDWARD | - | 59.46 | -2,000 | -118,920 |
| HERRIOTT JAMES | - | 59.46 | -1,500 | -89,190 |
| 累积净数量 | -3,500 | |||
| 累积净值 ($) | -208,110 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 59.46 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| DOYLE JAMES EDWARD | 董事 | 09 Oct 2025 | 自动卖出 (-) | 2,000 | 59.46 | 118,920 |
| HERRIOTT JAMES | 职员 | 09 Oct 2025 | 自动卖出 (-) | 1,500 | 59.46 | 89,190 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合